Showing results (71-80 of 95) with videos related to
Sort By:
Pageof 10
Annals of Translational Medicine|July 19, 2019
C1Q/TNF-related protein 4 expression correlates with herpes simplex encephalitis progressionWangshu Xu, Heng Zhou, Xiaojuan Li, et al.Frontiers in Neurology|September 25, 2020
Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum DisordersDe-Cai Tian, Yuwen Xiu, Xinli Wang, et al.The Lancet Regional Health. Western Pacific|August 9, 2023
A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM studyZhiguo Li, Chao Zhang, Ting Chang, et al.The Lancet Regional Health. Western Pacific|October 13, 2025
Corrigendum to A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study Lancet Reg Health West Pac (2023) 38: 100846Zhiguo Li, Chao Zhang, Ting Chang, et al.Neurology(R) Neuroimmunology & Neuroinflammation|August 8, 2020
Validation of the NEOS score in Chinese patients with anti-NMDAR encephalitisYujing Peng, Feifei Dai, Lei Liu, et al.Annals of Neurology|April 25, 2024
Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the Central Nervous SystemAi Guo, Zhe Zhang, Ge-Hong Dong, et al.Neurology(R) Neuroimmunology & Neuroinflammation|September 9, 2024
A Simple Score (MOG-AR) to Identify Individuals at High Risk of Relapse After MOGAD AttackYun Xu, Huaxing Meng, Moli Fan, et al.AJNR. American Journal of Neuroradiology|November 7, 2024
Imaging Transcriptomics of Brain Functional Alterations in MS and Neuromyelitis Optica Spectrum DisorderYuna Li, Jun Sun, Zhizheng Zhuo, et al.Neurology(R) Neuroimmunology & Neuroinflammation|June 7, 2020
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disordersMoli Fan, Wei Qiu, Bitao Bu, et al.The Lancet. Neurology|April 26, 2020
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trialChao Zhang, Meini Zhang, Wei Qiu, et al.Pageof 10